Edition:
United States

Eckert & Ziegler BEBIG SA (EZBG.BR)

EZBG.BR on Brussels Stock Exchange

10.00EUR
26 May 2017
Change (% chg)

-- (--)
Prev Close
€10.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
662
52-wk High
€11.50
52-wk Low
€6.20

EZBG.BR

Chart for EZBG.BR

About

Eckert & Ziegler BEBIG SA is a Belgium-based company involved in the active implantable medical devices segment of the health care sector. The Company designs, develops and distributes interstitial implants used in brachytherapy for the treatment of cancer. The Company produces and markets three lines of products: Permanent... (more)
No analyst recommendations are available for EZBG.BR.

Overall

Beta: 0.67
Market Cap(Mil.): €23.30
Shares Outstanding(Mil.): 2.33
Dividend: --
Yield (%): --

Financials

  EZBG.BR Industry Sector
P/E (TTM): 30.94 30.56 17.41
EPS (TTM): 0.32 -- --
ROI: 1.10 6.74 -5.42
ROE: 1.33 10.28 -4.68

BRIEF-Eckert & Ziegler Q1 sales up by 5% yoy to EUR 37.6 mln

* ECKERT & ZIEGLER: SALES GROWTH AND JUMP IN INCOME IN FIRST QUARTER

May 09 2017

BRIEF-Eckert & Ziegler signs agreement to sell its cyclotron division

* Signs agreement to sell its cyclotron division to Alliance Medical

May 05 2017

BRIEF-Eckert & Ziegler BEBIG FY EBITDA swings to profit of 2.7 million euros

* FY ebitda 2.7 million euros ($2.92 million) versus loss of 228,000 euros year ago

Mar 23 2017

BRIEF-Eckert & Ziegler posts FY sales of 138.0 million euros

* 2016 annual financial statements: sales and profit according to plan. Gross profit margin up by 6 pct. Change in the supervisory board.

Mar 23 2017

BRIEF-Eckert & Ziegler BEBIG announces end of shortage of iodine isotopes

* Announces that the shortage of iodine isotopes for production of its brachytherapy implantation seeds has been overcome Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 20 2017

More From Around the Web

Earnings vs. Estimates

No consensus analysis data available.